These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7714306)

  • 1. Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report).
    Slaap BR; van Vliet IM; Westenberg HG; den Boer JA
    J Affect Disord; 1995 Jan; 33(1):31-8. PubMed ID: 7714306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia.
    Bakish D
    J Clin Psychopharmacol; 1994 Feb; 14(1):74-5. PubMed ID: 8151007
    [No Abstract]   [Full Text] [Related]  

  • 3. MHPG and heart rate as correlates of nonresponse to drug therapy in panic disorder patients. A preliminary report.
    Slaap BR; van Vliet IM; Westenberg HG; Den Boer JA
    Psychopharmacology (Berl); 1996 Oct; 127(4):353-8. PubMed ID: 8923571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ondansetron in the treatment of panic disorder.
    Schneier FR; Garfinkel R; Kennedy B; Campeas R; Fallon B; Marshall R; O'Donnell L; Hogan T; Liebowitz MR
    Anxiety; 1996; 2(4):199-202. PubMed ID: 9160623
    [No Abstract]   [Full Text] [Related]  

  • 5. The structure of phobias in panic disorder.
    Argyle N; Solyom C; Solyom L
    Br J Psychiatry; 1991 Sep; 159():378-82. PubMed ID: 1958949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-injury related phobic avoidance as predictor of nonresponse to pharmacotherapy in panic disorder with agoraphobia.
    Overbeek T; Büchold H; Schruers K; Griez E
    J Affect Disord; 2004 Mar; 78(3):227-33. PubMed ID: 15013247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional classification of anxiety-panic.
    Liebowitz MR
    Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():47-52. PubMed ID: 7902853
    [No Abstract]   [Full Text] [Related]  

  • 8. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.
    van Vliet IM; Westenberg HG; Den Boer JA
    Psychopharmacology (Berl); 1993; 112(4):483-9. PubMed ID: 7871061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible monoamine oxidase-A inhibitors in panic disorder.
    Bakish D; Saxena BM; Bowen R; D'Souza J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline.
    Den Boer JA; Westenberg HG
    Int Clin Psychopharmacol; 1988 Jan; 3(1):59-74. PubMed ID: 2833543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
    Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
    Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fluvoxamine on panic disorder.
    Hoehn-Saric R; McLeod DR; Hipsley PA
    J Clin Psychopharmacol; 1993 Oct; 13(5):321-6. PubMed ID: 8227490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do panic symptoms during periods of remission predict relapse of panic disorder?
    Weisberg RB; Machan JT; Dyck IR; Keller MB
    J Nerv Ment Dis; 2002 Mar; 190(3):190-7. PubMed ID: 11923654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avoidant personality traits distinguish social phobic and panic disorder subjects.
    Noyes R; Woodman CL; Holt CS; Reich JH; Zimmerman MB
    J Nerv Ment Dis; 1995 Mar; 183(3):145-53. PubMed ID: 7891060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response.
    Slaap BR; van Vliet IM; Westenberg HG; Den Boer JA
    J Affect Disord; 1996 Jun; 39(1):13-9. PubMed ID: 8835649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diazepam and propranolol in panic disorder and agoraphobia.
    Noyes R; Anderson DJ; Clancy J; Crowe RR; Slymen DJ; Ghoneim MM; Hinrichs JV
    Arch Gen Psychiatry; 1984 Mar; 41(3):287-92. PubMed ID: 6367691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of agoraphobia.
    Pohl R; Berchou R; Rainey JM
    J Clin Psychopharmacol; 1982 Dec; 2(6):399-407. PubMed ID: 7174863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open trial of fluvoxamine therapy for panic disorder complicated by depression.
    Spiegel DA; Saeed SA; Bruce TJ
    J Clin Psychiatry; 1996; 57 Suppl 8():37-40; discussion 40-1. PubMed ID: 8698679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing panic disorder and agoraphobia from social phobia.
    Page AC
    J Nerv Ment Dis; 1994 Nov; 182(11):611-7. PubMed ID: 7964668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.